New way of identifying subtypes of Alzheimer's disease

Recently, scientists have published an article on early identification of the onset of progressive Alzheimer's disease in the journal Nature which also publishes some other studies on recombinant dog proteins, providing some basis for individual and precise treatment of Alzheimer's disease.

Researchers at the National Institutes of Health and the College of Neurology of the London College of Medicine have found that the type of fibrogenesis is associated with subtypes of Alzheimer's disease. A study published by them on nature described: the formation of brain tissue deposition of amyloid fibrils can reflect the physiological characteristics of Alzheimer's disease. The study found that the type of fiber with the degree of disease and pathological subtypes would show different morphological or size differences. According to this, we can classify the types of early Alzheimer's disease. This is a time-consuming and labor-intensive experimental project, so the relevant research is rare. To investigate the problem, the authors collected 37 tissue samples from the brain tissue of 18 dementia sufferers of the late Alzheimer's disease. They used magnetic resonance techniques to detect the deposition of these brain β-amyloid forms, while the clinical classification of these patients was compared. (Some patients were diagnosed with rapid progression; some patients were diagnosed as classic; and some patients had posterior cortical atrophy). The researchers found that classic patients with cerebral cortical atrophy have the same pattern with patients with cerebral β-amyloid deposition. However, the pattern of amyloid deposition in patients with rapid progression is often different from that of other types of patients.

The researchers believe that the rapid progress of Alzheimer's disease has a special β-like protein deposition pattern, resulting in the condition that the type of brain tissue in patients with fibrous lesions of the size and morphology are different from other types. This helps early identification of rapidly progressing Alzheimer's disease patients and gives them timely treatment. Researchers have also admitted that because the number of specimens is too small, the mechanism is not clear. Further studies remain to be carried out, and greater progress will be made. Flarebio provides you with superior recombinant proteins like recombinant ECEL1 at good prices.